Thane: Bajaj Healthcare Limited (BHL), a manufacturer of APIs,
Intermediates, and Formulations, has announced a successful competition of the first-ever pre-approval
inspection of the United States Food and Drug Administration (USFDA) at its API facility located at
Vadodara, Gujarat.
The inspection was held from November 14, 2022 to November 17, 2022.
“BHL is pleased to inform you that US Food and drug administration (USFDA) has conducted the pre-approval inspection of its API facility located at Vadodara, Gujarat, from November 14, 2022 to November
17, 2022,” the company said in a BSE filing.
17, 2022,” the company said in a BSE filing.
Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare
said, “I am happy to announce that we successfully completed the first-ever pre-approval USFDA inspection
with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are
committed to strict adherence to all applicable guidelines and regulations and maintaining the highest
quality standards in delivering quality services and timely delivery to our clients.”
said, “I am happy to announce that we successfully completed the first-ever pre-approval USFDA inspection
with ZERO 483 observation at our API Manufacturing facilities located at Vadodara, Gujarat. We are
committed to strict adherence to all applicable guidelines and regulations and maintaining the highest
quality standards in delivering quality services and timely delivery to our clients.”
Read also: Bajaj Healthcare enters highly regulated opiate processing business
Bajaj Healthcare Limited is a manufacturer of APIs, Intermediates, and Formulations established in 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has
state-of-art manufacturing facilities, of which six units are dedicated to APIs, two units to Intermediates, and 1 unit
for formulation. It has a strong presence globally in countries like Europe, the USA, Australia, Africa, the Middle
East, and South America.
state-of-art manufacturing facilities, of which six units are dedicated to APIs, two units to Intermediates, and 1 unit
for formulation. It has a strong presence globally in countries like Europe, the USA, Australia, Africa, the Middle
East, and South America.